News
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
02/17/2022 / 03:44 - GlobeNewswire - HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys About Lead Plaintiff Opportunity in Securities Class Action
02/14/2022 / 15:37 - GlobeNewswire - Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Telos, Fennec, and Astra Space and Encourages Investors to Contact the Firm
02/14/2022 / 03:00 - GlobeNewswire - HAGENS BERMAN BIIB ALERT: Investors in Biogen Inc. (BIIB) With Significant Losses Have Opportunity to Lead Securities Class Action
02/09/2022 / 02:11 - GlobeNewswire - Rain Therapeutics Continues to Strengthen its Leadership Team with Key Appointments
02/08/2022 / 14:00 - GlobeNewswire - BioCryst Appoints Machelle Sanders to Board of Directors
02/08/2022 / 13:00 - GlobeNewswire - Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global
02/08/2022 / 12:00 - GlobeNewswire - Block & Leviton LLP Has Filed a Lawsuit Against Biogen, Inc. for Securities Law Violations
02/08/2022 / 00:04 - GlobeNewswire - Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis
02/07/2022 / 22:05 - GlobeNewswire - Biogen Q4 revenue drops 4% YoY to land at $2.73B
02/03/2022 / 13:07 - TeleTrader
Real-time